Superworth

Tarsus Pharmaceuticals price to free cash flow TARS

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Nov 2, 2026
57.5×
5-year median
70.8×
Against its 5-year history
23rd
percentile: 0 is its lowest day, 100 its highest
5-year range
50.8× to 120×
Peer median
30.2×

Tarsus Pharmaceuticals' price to free cash flow is 57.5× as of Nov 2, 2026.

That is below its 5-year median of 70.8×, lower than on 77% of days in the last 5 years.

Over that time it ranged from 50.8× in Aug 2026 to 120× in Apr 2022.

The median for 10 biotech stocks of a similar size is 30.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far57.5×50.8×71.1×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202272.6×53.6×120×
202183.2×83.2×101×

Against its peers

Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
TARSTarsus Pharmaceuticals57.5×
ADMAAdma Biologics21.3×
VCELVericel33.6×
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
TECHBIO-TECHNE43.3×
MGTXMeiraGTx85.5×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
Peer median30.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Tarsus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.